A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT06659640 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Hemorrhagic Telangiectasia

Interventions

DRUG: ALN-6400
DRUG: Placebo

Sponsor

Alnylam Pharmaceuticals